AbCellera Biologics's total assets for Q1 2026 were $1.31B, a decrease of -3.67% from the previous quarter. ABCL total liabilities were $369.03M for the fiscal quarter, a -5.39% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.